Skip to search formSkip to main contentSkip to account menu

MK-7246

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Synthesis and preclinical evaluation of the CRTH2 antagonist [11C]MK-7246 as a novel PET tracer and potential surrogate marker for pancreatic beta-cell mass.
2014
2014
Anti-inflammatory actions of Chemoattractant Receptor-homologous molecule expressed on Th2 by the antagonist MK-7246 in a novel rat model of Alternaria alternata elicited pulmonary inflammation.
2013
2013
Pharmacological characterization of the late phase reduction in lung functions and correlations with microvascular leakage and lung edema in allergen-challenged Brown Norway rats.
Highly Cited
2012
Highly Cited
2012
CRTH2 antagonist MK-7246: a synthetic evolution from discovery through development.
In this paper, we report the development of different synthetic routes to MK-7246 (1) designed by the Process Chemistry group… 
2012
2012
UGT2B17 Genetic Polymorphisms Dramatically Affect the Pharmacokinetics of MK-7246 in Healthy Subjects in a First-in-Human Study
MK‐7246, an antagonist of the chemoattractant receptor on T helper type 2 (Th2) cells, is being developed for the treatment of… 
Highly Cited
2011
Highly Cited
2011
Pharmacological Characterization of MK-7246, a Potent and Selective CRTH2 (Chemoattractant Receptor-Homologous Molecule Expressed on T-Helper Type 2 Cells) Antagonist
The chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells (CRTH2) is a G protein-coupled receptor that… 
2011
2011
Azaindoles as potent CRTH2 receptor antagonists.
2011
2011
Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License